• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24006 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Austrian Institute for Health Technology Assessment (AIHTA) Hepatic and portal vein embolisation prior to major hepatectomy
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: chronic obstructive pulmonary disease- detection, diagnosis, optimal use of medications and inhalation devices, and global management]
2022     National Institute for Health and Care Excellence (NICE) Palforzia for treating peanut allergy in children and young people. NICE technology appraisal guidance 769
2022     Austrian Institute for Health Technology Assessment (AIHTA) Microwave ablation for liver tumours
2022     Austrian Institute for Health Technology Assessment (AIHTA) Osteopathy: effectiveness and safety for musculoskeletal pain and overview of training and quality requirements
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer. NICE technology appraisal guidance 770
2022     NIHR Health Technology Assessment programme Exercise to prevent shoulder problems after breast cancer surgery: the PROSPER RCT
2022     Austrian Institute for Health Technology Assessment (AIHTA) His-bundle-pacing for patients requiring a permanent pacemaker or cardiac resynchronisation
2022     National Institute for Health and Care Excellence (NICE) Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal). NICE technology appraisal guidance 771
2022     Austrian Institute for Health Technology Assessment (AIHTA) Chemosaturation with percutaneous hepatic perfusion for patients with liver cancer
2022     NIHR Health Technology Assessment programme SeHCAT (tauroselcholic [75selenium] acid) for the investigation of bile acid diarrhoea in adults: a systematic review and cost-effectiveness analysis
2022     National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapies. NICE technology appraisal guidance 772
2022     Austrian Institute for Health Technology Assessment (AIHTA) Lower esophageal sphincter devices for laparoscopic surgery in patients with gastroesophageal reflux disease (GERD)
2022     National Institute for Health and Care Excellence (NICE) Empagliflozin for treating chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 773
2022     Health Information and Quality Authority (HIQA) International review of clinical guidelines and models of care for long COVID
2022     Health Technology Wales (HTW) Convalescent plasma therapy for the treatment of COVID-19
2022     Belgian Health Care Knowledge Centre (KCE) Evaluation of Shingrix vaccine against herpes zoster
2022     National Institute for Health and Care Excellence (NICE) Lenalidomide for relapsed or refractory mantle cell lymphoma (terminated appraisal). NICE technology appraisal guidance 774
2022     Health Information and Quality Authority (HIQA) Update processes for guidelines – systematic review
2022     Health Technology Wales (HTW) Extreme hypofractionated radiotherapy (EHFRT) for localised prostate cancer
2022     Austrian Institute for Health Technology Assessment (AIHTA) Child and adolescent mental health care models: a scoping review
2022     National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic kidney disease. NICE technology appraisal guidance 775
2022     NIHR Health Technology Assessment programme Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT
2022     Austrian Institute for Health Technology Assessment (AIHTA) [Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess individual breast cancer risk, their utility and applicability in a breast cancer screening programme]
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: RASopathies Next-generation Sequencing Panel]
2022     National Institute for Health and Care Excellence (NICE) Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea. NICE technology appraisal guidance 776
2022     Health Information and Quality Authority (HIQA) COVID-19 Evidence Synthesis: International review of guidance on the use of face masks to mitigate the spread of SARS-CoV-2 infection
2022     National Institute for Health and Care Excellence (NICE) Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea. NICE technology appraisal guidance 777
2022     Health Technology Wales (HTW) Video laryngoscopes for use in pre-hospital care
2022     National Institute for Health and Care Excellence (NICE) Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 778
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Cardiac monitoring with textile wearable Holter for atrial fibrillation detection after cryptogenic stroke]
2022     National Institute for Health and Care Excellence (NICE) Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 779
2022     WorkSafeBC N-acetylcysteine (NAC) as treatment for complex regional pain syndrome (CRPS): 2022 Update
2022     National Institute for Health and Care Excellence (NICE) Nivolumab with ipilimumab for untreated advanced renal cell carcinoma. NICE technology appraisal guidance 780
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Peer support programs for youth mental health
2022     WorkSafeBC Antalgic gait, limp, osteoarthritis - what happens to the weight-bearing joints?
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Use of indocyanine green in colorectal and hepato-biliopancreatic surgery]
2022     National Institute for Health and Care Excellence (NICE) Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 781
2022     WorkSafeBC SANUWAVE therapy for wound healing
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Evaluation of several vaccination strategies against rotavirus in Spain. Safety, efficacy, effectiveness and efficiency]
2022     National Institute for Health and Care Excellence (NICE) Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal). NICE technology appraisal guidance 782
2022     WorkSafeBC Balloon spacer as treatment for massive rotator cuff tear
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Efficacy and safety of transanal irrigation in adults with bowel dysfunction]
2022     National Institute for Health and Care Excellence (NICE) Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. NICE technology appraisal guidance 783
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Internet-delivered cognitive behavioural therapy in the treatment of chronic non-cancer pain
2022     WorkSafeBC Satir brief transformational therapy as treatment for trauma-related disorders including PTSD
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for argininosuccinic aciduria (ASA)]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Systematic review on diagnosis and care of reactive attachment disorder]
2022     National Institute for Health and Care Excellence (NICE) Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer. NICE technology appraisal guidance 784
2022     Canadian Agency for Drugs and Technologies in Health (CADTH) Intraocular lens implantation for infants with aphakia: a systematic review of clinical effectiveness and cost-effectiveness
2022     National Institute for Health and Care Excellence (NICE) Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal). NICE technology appraisal guidance 785
2022     Norwegian Institute of Public Health (NIPH) [Intravenous ketamine for treatment-resistant depression and suicidal ideation: a single technology assessment - mapping]
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Safety and effectiveness of percutaneous tricuspid valve repair]
2022     National Institute for Health and Care Excellence (NICE) Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies. NICE technology appraisal guidance 786
2022     NIHR Health Technology Assessment programme The Best Services Trial (BeST?): Effectiveness and cost-effectiveness of the New Orleans Intervention Model for Infant Mental Health
2022     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Effectiveness of social distancing measures, in the context of the COVID-19]
2022     National Institute for Health and Care Excellence (NICE) Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE technology appraisal guidance 787
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Occupational exposures and asthma and COPD]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Treprostinil in chronic thromboembolic pulmonary hypertension (group 4)]
2022     The Regional Health Technology Assessment Centre (HTA-centrum) Osseointegrated upper limb prostheses with and without neuromuscular control: benefits and risks
2022     National Institute for Health and Care Excellence (NICE) Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy. NICE technology appraisal guidance 788
2022     Adelaide Health Technology Assessment (AHTA) Small gene panel testing for non-small cell lung carcinoma
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Irreversible electroporation in pancreatic cancer]
2022     The Regional Health Technology Assessment Centre (HTA-centrum) [Benefits and risks of caseload midwifery: continuity of midwifery team during antenatal, intrapartal, and postnatal care]
2022     National Institute for Health and Care Excellence (NICE) Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations. NICE technology appraisal guidance 789
2022     NIHR Health Technology Assessment programme A rapid intrapartum test for group B Streptococcus to reduce antibiotic usage in mothers with risk factors: the GBS2 cluster RCT
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: integration of real-world data and evidence into assessments to support decision-making in the pharmaceutical sector]
2022     Austrian Institute for Health Technology Assessment (AIHTA) Quality registries in dementia care: mapping of registries to improve quality and service delivery
2022     Adelaide Health Technology Assessment (AHTA) Whole genome sequencing of antimicrobial-resistant pathogens
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Digital breast tomosynthesis]
2022     The Regional Health Technology Assessment Centre (HTA-centrum) Active or semi-active robotic arm-assisted versus manual knee arthroplasty: benefits and risks
2022     National Institute for Health and Care Excellence (NICE) TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal). NICE technology appraisal guidance 790
2022     Penn Medicine Center for Evidence-based Practice (CEP) Medications for treating moderate to severe alcohol withdrawal syndrome in critical care and emergency department patients
2022     Adelaide Health Technology Assessment (AHTA) Genetic testing for childhood hearing impairment
2022     Malaysian Health Technology Assessment (MaHTAS) Molecular profiling assays in early breast cancer
2022     The Regional Health Technology Assessment Centre (HTA-centrum) Effectiveness and safety of surgical procedures to treat apical prolapse - comparison of sacrospinous fixation, laparoscopic sacrocolpopexy/sacrohysteropexy, and the Manchester procedure
2022     National Institute for Health and Care Excellence (NICE) Romosozumab for treating severe osteoporosis. NICE technology appraisal guidance 791
2022     Penn Medicine Center for Evidence-based Practice (CEP) Guidelines and clinical pathways for management of upper GI bleeding
2022     Malaysian Health Technology Assessment (MaHTAS) Immunotherapy for PD-L1 positive advanced non-small cell lung cancer
2022     National Institute for Health and Care Excellence (NICE) Filgotinib for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 792
2022     NIHR Health Technology Assessment programme Assessing the efficacy and safety of methotrexate vs ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema in children Taskforce (TREAT) randomised controlled trial
2022     NIHR Health Technology Assessment programme Moulded cast compared with K-wire fixation after manipulation of an acute dorsally displaced distal radius fracture: the DRAFFT 2 RCT
2022     Penn Medicine Center for Evidence-based Practice (CEP) Peripartum or postnatal care disparities and equity
2022     Malaysian Health Technology Assessment (MaHTAS) Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for non-small cell lung cancer
2022     National Institute for Health and Care Excellence (NICE) Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal). NICE technology appraisal guidance 793
2022     NIHR Health Technology Assessment programme EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation
2022     Malaysian Health Technology Assessment (MaHTAS) Robotic arm-assisted surgery in total hip arthroplasty, total knee arthroplasty and unicompartmental knee arthroplasty
2022     National Institute for Health and Care Excellence (NICE) Diroximel fumarate for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 794
2022     WorkSafeBC Clinical accuracy of rapid antigen tests for COVID-19
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Ambulatory blood pressure monitoring (ABPM) in the identification of circadian patterns in patients with arterial hypertension: evaluation of safety, effectiveness, and efficiency]
2022     National Institute for Health and Care Excellence (NICE) Ibrutinib for treating Waldenstrom's macroglobulinaemia. NICE technology appraisal guidance 795
2022     Penn Medicine Center for Evidence-based Practice (CEP) Workplace violence in healthcare settings
2022     WorkSafeBC Functional neurology as treatment for post-traumatic brain injury
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of teleconsultation in primary care, and the organizational, ethical, social, and legal aspects linked to its use]
2022     National Institute for Health and Care Excellence (NICE) Venetoclax for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 796
2022     Health Technology Wales (HTW) Electronic blood management systems for blood transfusions
2022     WorkSafeBC Dupuytren's contracture and wrist fractures
2022     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the safety, efficacy/effectiveness, and efficiency of stereotactic body radiation therapy (SBRT) in lung, prostate, and liver cancer]
2022     National Institute for Health and Care Excellence (NICE) Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal). NICE technology appraisal guidance 797
2022     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: evaluation of Synvisc and Synvisc One for the management of knee osteoarthritis]